Colonic Diseases Clinical Trial
— MA-53Official title:
Evaluation of PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon
NCT number | NCT00604162 |
Other study ID # | MA-53 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | October 2006 |
Est. completion date | October 2007 |
Verified date | August 2010 |
Source | Medtronic - MITG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To see if PillCam COLON will demonstrate diagnostic yield >80% in detecting significant colonic pathologies when compared to colonoscopy in the target population.
Status | Completed |
Enrollment | 332 |
Est. completion date | October 2007 |
Est. primary completion date | October 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Subject was referred for colonoscopy for one of the following reasons: - Subjects over = 50 years of age with one or more of the following clinical symptoms: rectal bleeding, hematochezia, melena, positive Fecal Occoult Blood Test (FOBT), recent change of bowel habits, or diarrhea/constipation of recent onset. - Any subject = 18 years of age with: - Positive findings in the colon on a GastroIntestinal (GI) radiographic study - Personal history of colorectal cancer (CRC) or adenomatous colonic polyps and at least 3 years since last colonoscopy - Suspected or known ulcerative colitis Exclusion Criteria: - Subject has dysphagia - Subject has congestive heart failure - Subject has renal insufficiency - Subject is known or is suspected to suffer from intestinal obstruction. - Chronic use of laxatives - Subject has a cardiac pacemakers or other implanted electro medical devices. - Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception. - Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule. - Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator. - Subject has any condition, which precludes compliance with study and/or device instructions. - Age < 18 years - Subject suffers from life threatening conditions - Subject is currently participating in another clinical study - Subject has known slow gastric emptying time |
Country | Name | City | State |
---|---|---|---|
France | CHU Lyon | Lyon | |
France | CHU Nancy | Nancy | |
Germany | Evangelisches Krankenhaus | Dusseldorf | |
Germany | AK Altona | Hamburg | |
Italy | Ospedale Gemelli | Rome | |
Spain | Clinica Universitaria de Navarra | Pamplona | |
United Kingdom | St.Marks&Northwick Park hospital | Harrow |
Lead Sponsor | Collaborator |
---|---|
Medtronic - MITG |
France, Germany, Italy, Spain, United Kingdom,
Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, Costamagna G, Riccioni ME, Spada C, Petruzziello L, Fraser C, Postgate A, Fitzpatrick A, Hagenmuller F, Keuchel M, Schoofs N, Dev — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies | The number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported. | 1 day | |
Primary | Number of Participants With Indicated Lesions Detected by Standard Colonoscopy | Since the standard colonoscopy is the "gold standard" to which the PillCam is to be compared, the number of participants with the indicated lesions identified by a trained clinician using standard colonoscopy procedures is reported here. Note that some Participants had multiple lesions and so could be included in more than one size category. Advanced adenoma is defined as 1) an adenoma 1 cm or larger or 2) an adenoma with villous features or high-grade dysplasia. All colorectal cancers were 6mm or larger. | 1 day | |
Primary | Sensitivity of Capsule Endoscopy for Indicated Lesions | Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Sensitivity was calculated as the percentage of participants who had positive findings on capsule endoscopy (of a specified category) among those participants who had positive findings on colonoscopy of the same category (reported in Outcome Measure 1). The false negative rate is equal to 1 - sensitivity and indicated the percentage of lesions missed by capsule endoscopy. | 1 day | |
Primary | Specificity of Capsule Endoscopy for Indicated Lesions | Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Specificity was calculated as the percentage of participants who had negative findings on capsule endoscopy (of a specified category) among participants with negative colonoscopy findings of the same category (reported in Outcome Measure 1). This corresponds to 1 - the false positive rate. | 1 day | |
Secondary | Percent of Participants With Scoring Index 3 or 4 | Overall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows: poor cleansing level (Large amount of fecal residue.) fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.) good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.) excellent cleansing level (No more than small bits of adherent feces.) |
1 day | |
Secondary | Number, Type and Severity of Adverse Events | Within 7 days | ||
Secondary | Accuracy Parameters (Sensitivity, Specificity, Negative Predicted Value, Positive Predicted Value) of Colon Capsule Endoscopy, Compared to Standard Colonoscopy | within 7 days | ||
Secondary | Percentage of Excreted Colon Capsules | Within 7 days | ||
Secondary | Colon Capsule Endoscopy Transit Time Per Section (Stomach, Small Bowel, Colon) | within 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Terminated |
NCT01119027 -
Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills
|
N/A | |
Completed |
NCT01063231 -
Evaluation of PillCam™ Colon 2 in Visualization of the Colon
|
Phase 3 | |
Completed |
NCT04074577 -
Computer Aided Detection, Tandem Colonoscopy Study
|
N/A | |
Not yet recruiting |
NCT04087824 -
Deep Learning Algorithm for Recognition of Colonic Segments.
|
N/A | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT02503631 -
Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
|
||
Completed |
NCT01600209 -
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
|
N/A | |
Completed |
NCT01260168 -
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
|
N/A | |
Recruiting |
NCT04598880 -
Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing
|
Phase 4 | |
Completed |
NCT01738425 -
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT02291445 -
Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study
|
Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03139942 -
Optical Polyp Testing for In Vivo Classification
|
N/A | |
Completed |
NCT04263818 -
Endoscopist and Endoscope Motions During Colonoscopy
|
N/A | |
Recruiting |
NCT05923918 -
A Study to Evaluate Safety and Efficacy of PBK_M2101
|
Phase 3 | |
Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01397747 -
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
|
N/A |